Ningning Yan
Siyuan Huang†
Sanxing Guo
Xingya Li
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
- Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
A Corrigendum on
Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
by Yan N, Huang S, Li L, Guo Q, Geng D, Zhang H, Guo S and Li X (2022). Front. Pharmacol. 13:898623. doi: 10.3389/fphar.2022.898623
In the published article, the names in the Author list were incorrectly written as “Ning Yan*†, Si Huang†, Lin Li, Qian Guo, Di Geng, Hui Zhang, San Guo* and Xing Li*.” The correct spelling is “Ningning Yan*†, Siyuan Huang†, Linlin Li, Qianqian Guo, Di Geng, Huixian Zhang, Sanxing Guo* and Xingya Li*.” The updated Author Contributions statement appears below.
“All authors participated in the diagnosis and treatment process. NY, SH, and XL diagnosed the patient and developed the treatment plan. NY, SH, LL, QG, DG, and HZ participated in the follow-up course. NY, SH, SG, and XL wrote the original manuscript. All authors contributed to the article and approved the submitted version.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: immune checkpoint inhibitor, NSCLC, ROS1, chemo-immunotherapy, lung adenocarcinoma
Citation: Yan N, Huang S, Li L, Guo Q, Geng D, Zhang H, Guo S and Li X (2023) Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report. Front. Pharmacol. 14:1256801. doi: 10.3389/fphar.2023.1256801
Received: 20 July 2023; Accepted: 21 July 2023;
Published: 26 July 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Yan, Huang, Li, Guo, Geng, Zhang, Guo and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ningning Yan, eWFubmluZ3JqQGFsdW1uaS5zanR1LmVkdS5jbg==; Xingya Li, ZmNjbGl4eTFAenp1LmVkdS5jbg==; Sanxing Guo, c2FueGluZzEzNEBob3RtYWlsLmNvbQ==
†These authors have contributed equally to this work and share first authorship